FDA Approved Drugs by Medical Condition

Search by medical condition for drugs approved by the Food and Drug Administration (FDA) for sale in the United States. Select the letter below that corresponds to the first letter of the medical condition you are searching for and all approved drugs classified under that category will be listed below.

Vaccines

Bexsero (Meningococcal Group B Vaccine) (by Novartis), Approved January 2015
For the treatment of invasive meningococcal disease caused by serogroup B

Flublok (seasonal influenza vaccine) (by Protein Sciences), Approved January 2013
For the active immunization against influenza virus subtypes A and type B

Flucelvax, Influenza Virus Vaccine (by Novartis), Approved November 2012
For the treatment of influenza virus subtypes A and type B

Fluzone Preservative-free (by Sanofi Pasteur), Approved September 2002
Preservative free, pediatric dose, influenza virus vaccine for the immunization of infants

Pediarix Vaccine (by GlaxoSmithKline), Approved December 2002
For the prevention of diphtheria, tetanus, pertussi, polio and hepatitis B in children 6 weeks to 7 years old.

Shingrix (Zoster Vaccine Recombinant, Adjuvanted) (by GlaxoSmithKline), Approved October 2017
For the prevention of herpes zoster (shingles)

Tripedia (Diptheria and Tetanus Toxoids and Acellular Pertussis Vaccine Absorbed) (by Connaught Laboratories), Approved August 1996
Treatment for whooping cough

VariZIG, Varicella Zoster Immune Globulin (Human) (by Cangene), Approved January 2013
For the post-exposure prophylaxis of varicella zoster (chickenpox)

Vaxchora (Cholera Vaccine, Live, Oral) (by PaxVax), Approved June 2016
For active immunization against Cholera

Vaginal Atrophy

Intrarosa (prasterone vaginal insert) (by Endoceutics), Approved November 2016
For the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause

Osphena (ospemifene) (by Shionogi), Approved March 2013
For the treatment of dyspareunia and vulvar and vaginal atrophy due to menopause

Vaginal Infection

FEMSTAT One (by Roche), Approved Februrary 1997
Treatment for vaginal yeast infections

Metronidazole 1.3% Vaginal Gel (by Actavis, Inc.), Approved April 2014
For the treatment of bacterial vaginosis

Monistat 3 (miconazole nitrate) (by Johnson & Johnson), Approved April 1996
Over the counter treatment for vaginal yeast infections

Solosec (secnidazole) (by Symbiomix Therapeutics), Approved September 2017
For the treatment of bacterial vaginosis

Varicose Veins

Varithena (polidocanol injectable foam) (by BTG plc), November 2013
For the treatment of varicose veins

Vascular Diseases

Yosprala (aspirin and omeprazole) (by Aralez Pharmaceuticals), Approved September 2016
For the prevention of cardiovascular and cerebrovascular events

Venous Thromboembolism

Bevyxxa (betrixaban) (by Portola Pharmaceuticals), Approved June 2017
For the the prophylaxis of venous thromboembolism

Viral Infections

Benznidazole (by Chemo Group), Approved August 2017
For the treatment of Chagas disease

KedRab [Rabies Immune Globulin (Human)] (by Kedrion Biopharma ), Approved August 2017
For the post-exposure prophylaxis of rabies infection

Vitamin Deficiency

Nascobal Gel (Cyanocobalamin, USP) (by Questcor Pharmaceuticals), Approved November 1996
Treatment for vitamin B-12 deficiency

Vomiting

Akynzeo (netupitant and palonosetron) (by Helsinn), Approved October 2014
For the prevention of chemotherapy-induced nausea and vomiting

Diclegis (doxylamine succinate + pyridoxine hydrochloride DR tablets) (by Duchesnay USA), Approved April 2013
For the treatment of nausea and vomiting of pregnancy

Sustol (granisetron) (by Heron Therapeutics), Approved August 2016
For the prevention of chemotherapy-induced nausea and vomiting

Syndros (dronabinol oral solution) (by Insys Therapeutics), Approved July 2016
For the treatment of anorexia associated with AIDS and nausea and vomiting associated with cancer chemotherapy

Varubi (rolapitant) (by Tesaro), Approved September 2015
For the prevention of delayed nausea and vomiting associated with chemotherapy

Von Willebrand Disease

Wilate (von Willebrand Factor/Coagulation Factor VIII Complex (Human) (by Octapharma), Approved December of 2009
For the treatment of von Willebrand disease